Laurence H. If you are the author of this article you still need to obtain permission to reproduce the whole article in a third party publication with the exception of reproduction of the whole article in a thesis or dissertation. Cited by. SYD results in decreased tumor growth in a BT mouse xenograft in vivo and is stable in human and cynomolgus monkey plasma. Two duocarmycin analogs: CC and duocarmycin SA with highlighted pharmacological active units Toxins,
The duocarmycins are members of a series of related natural products first isolated from Streptomyces bacteria in They are notable for their extreme cytotoxicity and thus represent a class of exceptionally potent antitumour antibiotics.
Duocarmycins Creative Biolabs
1 Biological activity; 2 Duocarmycin analogues vs tubulin binders. Read · Edit · View history. Nitro seco Analogues of the Duocarmycins Containing Sulfonate Leaving Groups as Hypoxia-Activated Prodrugs for Cancer Therapy. Journal.
A new class of DNA alkylating agents is described that incorporate the quinone of the mitomycins, which is thought to impart tumor cell selectivity as a result of.
Two duocarmycin analogs: CC and duocarmycin SA with highlighted pharmacological active units Toxins, Cancer Research.
Growing evidence suggests that DNA damaging agents, such as duocarmycins, are more efficacious in tumor cell killing than tubulin binders, particularly in case of solid tumors.
Video: Duocarmycin analogues of history
Kiakos, J. Patterson Bradford. Scientists at The Netherlands-based Synthon formerly Syntarga have combined a unique linkers with duocarmycin derivatives that have a hydroxyl group which is crucial for biological activity.
Go to our Instructions for using Copyright Clearance Center page for details.
of DNA-Alkylating Duocarmycin Analogues by High-Resolution Mass Spectrometry of Highly Potent Glycosidic Duocarmycin Analogues for Selective Cancer Therapy First published: 8 September Full publication history; DOI. First published: 7 December Full publication history; DOI: /chem. View/save citation; Cited by (CrossRef): 4 articles Check for updates.
November 26, For price inquiries, please feel free to contact us through the form on the left side.
Sugiyama, H. If you are not the author of this article and you wish to reproduce material from it in a third party non-RSC publication you must formally request permission using Copyright Clearance Center. From the journal: Chemical Communications.
Expert Opinion on Therapeutic Patents.